Looking at the results released by Novo Nordisk and listening to the call anyone who’s been following this company for more than a few years must feel like the world has turned upside down. While it’s difficult to imagine today it wasn’t that long ago that insulin sales were driving Novo and GLP-1 sales were a mere afterthought. Today the exact opposite is true, now that insulin has fully commoditized sales of insulin are a mere afterthought while sales of GLP-1 continue to fuel the Novo earnings engine.
Sales of Ozempic® their once weekly GLP . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.